## Drug Discovery Technology (1/3)



(Revised August 7, 2025)

PROTACs, molecular glue	<ul> <li>Efficient evaluation method for degraders</li> <li>Technologies that can comprehensively analyze on-target and off-target</li> <li>Technology to discover targets for degradative drivers (excludes cancer and tumors)</li> <li>Technology to reach the target tissue (such as CNS)</li> </ul>
Small Molecules Targeting RNA	<ul> <li>Method for measuring the binding affinity of RNA-targeting small molecules with in vivo relevance</li> <li>Excludes SPR, ITC, MST, AS-MS and SHAPE</li> <li>High through put in silico screening technology for RNA</li> <li>Efficient method for evaluating the three-dimensional structure of RNA</li> </ul>
Drug discovery method aimed at covalent binders	<ul> <li>Fundamental technologies</li> <li>Evaluation methods for drug discovery</li> </ul>
Screening and Synthesis Automation Technologies	<ul> <li>Virtual screening methods that can screen a large-scale virtual library with high accuracy and speed</li> <li>Operate throughout the day</li> </ul>

## Drug Discovery Technology (2/3)



(Revised August 7, 2025)

Peptide Therapeutics	<ul> <li>Identification of intracellular PPI targets</li> <li>Efficient method for transferring peptide drug molecules into cells</li> <li>Technology for highly accurate docking (SBDD) and simulation (LBDD) of peptide drug molecules</li> </ul>
Antibody Therapeutics	<ul> <li>Technology to deliver antibodies into brain</li> <li>Discovery of novel target molecules for antibody drug development         <ul> <li>Chronic infectious diseases</li> <li>Central nervous system diseases</li> <li>Motor dysfunction diseases</li> </ul> </li> </ul>
Nucleic Acid Therapeutics	<ul> <li>Neurodegenerative diseases and motor dysfunction diseases for siRNA therapeutics</li> <li>Deliver siRNA into the brain and immune cells</li> </ul>

## Drug Discovery Technology (3/3)



(Revised August 7, 2025)

Pharmacokinetics	<ul> <li>In vitro assay for predicting human biliary clearance and enterohepatic circulation</li> <li>Drug transport and drug-drug interaction (DDI) risk prediction models using human P-gp/BCRP transgenic or knock-in animals</li> <li>Intracellular drug quantification for PK/PD and MoA insights</li> <li>Predict the risk of P-gp or BCRP inhibitory effects on drug absorption and disposition</li> </ul>
Safety	<ul> <li>AI system to classify biochemical toxicity data as adverse or non-adverse</li> <li>In silico toxicity mechanism analysis system</li> <li>Predicting toxicity target organs using live animal image diagnosis (CT, MRI, etc.)</li> <li>In vitro model for ocular toxicity evaluation and mechanism analysis</li> <li>In vitro evaluation system to evaluate damage and regeneration of inner ear hair cells</li> <li>In vivo evaluation system for ototoxicity using ABR (Auditory Brainstem Response)</li> <li>Ames avoidance measures and prediction tools in nucleic acid analog drug discovery</li> </ul>
Drug Discovery Platforn Technologies	<ul> <li>Method for screening and optimizing enzyme activity based on substrate specificity of metabolite biosynthetic enzymes</li> <li>Bioinformatics techniques including enzyme sequence data</li> <li>Data-driven optimization for reproducible scale-up cultivation</li> </ul>